Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss excluding compensation and derivative-value issues), roughly in line with analyst expectations of a $0.22-$0.25 loss. The late-stage biopharma noted an FDA approval for a use of its Vascepa capsules in treating hypertriglyceridemia, and the development of eight new patents to go alone with 30 other applications pending.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs